Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparison of therapy‐related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group study

6 Apr 2020

Abstract excerpt

This multi-institutional study retrospectively evaluated clinicopathologic and genetic characteristics in 351 patients with core-binding-factor acute myeloid leukemia (CBF-AML), comprising 69 therapy-related (t-CBF-AML) and 282 de novo cases. The T-CBF-AML patients were older, had lower WBC counts, and slightly higher hemoglobin than patients with de novo disease. Secondary cytogenetic abnormalities were more...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Chronic Myeloid Leukemia Treatments
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32249963
DOI: 10.1002/ajh.25814

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparison of therapy‐related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group studyPMID 32249963Read ↗

Genetic abnormalities predict outcomes in patients with core binding factor acute myeloid leukemiaSemantic proximity Read ↗

[The impact of KIT and other concomitant gene mutations on the prognoses of patients with core-binding factor acute myeloid leukemia].Semantic proximity Read ↗

[Prognostic value of KIT and other clonal genetic mutations in core-binding factor acute myeloid leukemia].Semantic proximity Read ↗

Core‐binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapySemantic proximity Read ↗

Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years.Semantic proximity Read ↗

Next-generation sequencing with a myeloid gene panel in core-binding factor AML showed KIT activation loop and TET2 mutations predictive of outcome.Semantic proximity Read ↗

Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemiaSemantic proximity Read ↗

Clinicopathologic and Molecular Analysis of Normal Karyotype Therapy-Related and De Novo Acute Myeloid Leukemia: A Multi-Institutional Study by the Bone Marrow Pathology GroupSemantic proximity Read ↗

Comprehensive mutational profiling of core binding factor acute myeloid leukemia.Semantic proximity Read ↗

Genetic and Genomic Landscape of Secondary and Therapy-Related Acute Myeloid Leukemia.Semantic proximity Read ↗

Genomic mutation patterns and prognostic value in de novo and secondary acute myeloid leukemia: A multicenter study from China.Semantic proximity Read ↗

Core-binding factor acute myeloid leukemia: can we improve on HiDAC consolidation?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.